Advanced
A New Entry to β-Functionalization of Enones: Pentyloxy Group Incorporation in the TBSOTf-Mediated Ring-Opening Reaction of Epoxides with Ylides Derived from the Phosphoniosilylation Products of Enones in Tetrahydropyran
A New Entry to β-Functionalization of Enones: Pentyloxy Group Incorporation in the TBSOTf-Mediated Ring-Opening Reaction of Epoxides with Ylides Derived from the Phosphoniosilylation Products of Enones in Tetrahydropyran
Bulletin of the Korean Chemical Society. 2014. Aug, 35(8): 2573-2576
Copyright © 2014, Korea Chemical Society
  • Received : March 17, 2014
  • Accepted : April 23, 2014
  • Published : August 20, 2014
Download
PDF
e-PUB
PubReader
PPT
Export by style
Article
Author
Metrics
Cited by
TagCloud
About the Authors
Su Jin Oh
Sun Ho Jung

Abstract
Keywords
PPT Slide
Lager Image
PPT Slide
Lager Image
PPT Slide
Lager Image
Experimental Section
3-{5-[2-(tert-Butyldimethylsilanyloxy)-3-phenylpropoxy]-pentyl}-cyclopent-2-enone (7aq, entry 2, general procedure). To a solution of triphenylphosphine (144 mg, 0.55 mmol) in tetrahydropyran 8 (2.0 mL) were added TBSOTf (126 µL, 0.55 mmol) and 2-cyclopenten-1-one 5a (42 µL, 0.50 mmol). After being stirred at room temperature for 1.5 h, the reaction mixture was cooled to −45 ℃ and n-butyllithium (419 µL, 1.55 M in hexanes, 0.65 mmol) was added dropwise to give a dark brown-colored solution. After the mixture being stirred for 1 h, (2,3-epoxypropyl)benzene 3q (132 µL, 1.00 mmol) and TBSOTf (230 µL, 1.00 mmol) were added dropwise at −78 ℃ (bath temperature). The reaction mixture was stirred for 1 h, and then water (1 mL) and triethylamine (209 µL, 1.50 mmol) were added. After being warmed to room temperature, the reaction mixture was stirred for 1 h. The usual extractive work-up and flash column chromatography (hexane:EtOAc = 5:1 → 3:1) gave 7aq (160 mg, 77%). 1 H NMR (500 MHz, CDCl 3 ) δ 7.47–7.51 (m, 3H), 7.42 (m, 2H), 6.18 (s, 1H), 4.18 (m, 1H), 3.65 (m, 2H), 3.50–3.59 (m, 2H), 3.11 (m, 1H), 2.89 (m, 1H), 2.80 (m, 2H), 2.62–2.66 (m, 4H), 1.82–1.86 (m, 4H), 1.65 (m, 2H), 1.04 (s, 9H), 0.16 (s, 3H), 0.00 (s, 3H). 13 C NMR (125 MHz, CDCl 3 ) δ 210.9, 183.7, 138.2, 129.6, 128.7, 128.3, 126.8, 74.3, 71.6, 71.4, 41.6, 40.1, 35.5, 33.7, 31.8, 29.7, 29.4, 27.2, 27.1, 26.3, 26.1, −4.5, −5.0. FT-IR (neat) 3422, 3026, 2929, 2859, 1702, 1672, 1611, 1495, 1453, 1435, 1407, 1337, 1283, 1236, 1183, 1117, 1080, 1030, 989, 842, 744, 699, 604, 541, 503 cm −1 . ESI MS ( m/z ) 417.3 [M+1] + .
Other compounds were prepared similarly, and the spectroscopic data of selected compounds are shown as follows.
3-{5-[2-(tert-Butyldimethylsilanyloxy)butoxy]-pentyl}-cyclopent-2-enone (7ap, entry 1). 1 H NMR (500 MHz, CDCl 3 ) δ 5.95 (s, 1H), 3.71 (m, 1H), 3.42 (t, J = 6.6 Hz, 2H), 3.32 (m, 2H), 2.58 (m, 2H), 2.39–2.43 (m, 4H), 1.50–1.70 (m, 5H), 1.38–1.44 (m, 3H), 0.93 (t, J = 6.6 Hz, 3H), 0.89 (s, 9H), 0.06 (s, 6H).). FT-IR (neat) 2932, 2863, 1703, 1672, 1609, 1460, 1435, 1406, 1237, 1184, 1109, 987, 919, 843, 480 cm −1 . ESI MS ( m/z ) 355.3 [M+1] + .
3-{5-[2-(tert-Butyldimethylsilanyloxy)-3-(methoxyphenyl) propoxy]-pentyl}-cyclopent-2-enone (7ar, entry 3). 1 H NMR (500 MHz, CDCl 3 ) δ 7.10 (d, J = 6.6 Hz, 2H), 6.80 (d, J = 6.6 Hz, 2H), 5.95 (s, 1H), 3.88–3.92 (m, 1H), 3.79 (s, 3H), 3.38–3.42 (m, 2H), 3.23–3.35 (m, 2H), 2.82 (dd, J = 13.6, 5.0 Hz, 1H), 2.55–2.65 (m, 3H), 2.38–2.45 (m, 4H), 1.54–1.67 (m, 4H), 1.40–1.45 (m, 2H), 0.83 (s, 9H), −0.08 (s, 3H), −0.18 (s, 3H). 13 C NMR (125 MHz, CDCl 3 ) δ 210.5, 183.3, 158.3, 131.1, 131.0, 131.0, 129.7, 113.7, 74.9, 73.1, 71.4, 55.5, 40.6, 35.6, 33.7, 31.8, 29.7, 27.2, 26.3, 18.4, −4.5, −4.8. FT-IR (neat) 2927, 2855, 1707, 1674, 1613, 1511, 1462, 1438, 1299, 1245, 1178, 1107, 1035, 992, 939, 830, 774, 723, 663, 523 cm −1 . ESI MS ( m/z ) 447.3 [M+1] + .
3-{5-[2-(tert-Butyldimethylsilanyloxy)-3-isopropoxypropoxy]-pentyl}-cyclopent-2-enone (7as, entry 4). 1 H NMR (500 MHz, CDCl 3 ) δ 5.89 (s, 1H), 3.83 (m, 1H), 3.52 (m, 1H), 3.37–3.41 (m, 4H), 3.29 (m, 2H), 2.56 (m, 2H), 2.31–2.40 (m, 4H), 1.48–1.62 (m, 4H), 1.35 (m, 2H), 1.04–1.12 (2d, 6H), 0.83 (m, 9H), 0.02 (s, 6H). 13 C NMR (125 MHz, CDCl 3 ) δ 206.4, 179.3, 125.8, 69.6, 68.2, 67.7, 67.5, 66.6, 31.6, 29.8, 27.8, 25.8, 23.2, 22.3, 22.2, 22.0, 18.4, 14.6, −8.3, −8.5. FT-IR (neat) 2928, 2856, 1709, 1674, 1616, 1462, 1438, 1409, 1367, 1335, 1249, 1180, 1119, 1004, 938, 833, 811, 776, 666, 573, 476 cm −1 . ESI MS ( m/z ) 399.3 [M+1] + .
3-{5-[2-(tert-Butyldimethylsilanyloxy)-cyclohexyloxy]-pentyl}-cyclopent-2-enone (7au, entry 6). 1 H NMR (500 MHz, CDCl 3 ) δ 5.88 (s, 1H), 3.31–3.52 (m, 3H), 2.96 (m, 1H), 2.45–2.57 (m, 2H), 2.28–2.39 (m, 4H), 1.87 (m, 1H), 1.79 (m, 1H), 1.46–1.65 (m, 6H), 1.28–1.42 (m, 2H), 1.20–1.27 (m, 4H), 0.89 (s, 9H), 0.06 (s, 3H), 0.01 (s, 3H). 13 C NMR (125 MHz, CDCl 3 ) δ 206.4, 179.3, 125.8, 78.4, 70.2, 65.8, 31.6, 29.9, 27.8, 26.3, 25.7, 23.3, 22.3, 22.2, 22.1, 19.8, 19.6, 14.4, −8.2, −8.4. FT-IR (neat) 2928, 2856, 1708, 1674, 1616, 1471, 1462, 1437, 1408, 1375, 1359, 1248, 1181, 1159, 1095, 1021, 1005, 938, 873, 833, 774, 721, 666, 542, 440 cm −1 . ESI MS ( m/z ) 381.3 [M+1] + .
{5-[2-(tert-Butyldimethylsilanyloxy)-3-butoxy]-pentyl}-cyclohex-2-enone (7bp, entry 7). 1 H NMR (500 MHz, CDCl 3 ) δ 5.87 (s, 1H), 3.67–3.77 (m, 1H), 3.41 (t, J = 6.5 Hz, 2H), 3.20–3.40 (m, 2H), 2.36 (t, J = 6.7 Hz, 2H), 2.28 (t, J = 6.1 Hz, 2H), 2.21 (t, J = 7.7 Hz, 2H), 1.99 (m, 2H), 1.45–1.56 (m, 4H), 1.44 (m, 1H), 1.37 (m, 3H), 0.92 (t, J = 7.5 Hz, 3H), 0.90 (s, 9H), 0.10 (s, 3H), 0.06 (s, 3H). 13 C NMR (125 MHz, CDCl 3 ) δ 200.3, 166.9, 125.9, 75.4, 72.9, 71.4, 38.3, 37.6, 29.9, 29.6, 27.7, 27.0, 26.9, 25.9, 23.0, 18.5, 9.88, −4.2, −4.5. FT-IR (neat) 2932, 2861, 1663, 1622, 1455, 1437, 1373, 1347, 1324, 1253, 1190, 1117, 1028, 965, 886, 755, 720, 694, 538, 502 cm −1 . ESI MS ( m/z ) 369.3 [M+1] + .
3-{5-[2-(tert-Butyldimethylsilanyloxy)-3-phenylpropoxy]-pentyl}-cyclohex-2-enone (7bq, entry 8). 1 H NMR (500 MHz, CDCl 3 ) δ 7.25 (m, 2H), 7.19 (m, 3H), 5.88 (s, 1H), 3.95 (m, 1H), 3.42 (td, J = 6.5, 2.8 Hz, 2H), 3.24–3.38 (m, 2H), 2.89 (dd, J = 13.5, 4.7 Hz, 1H), 2.65 (dd, J = 13.4, 7.6 Hz, 1H), 2.36 (t, J = 6.7 Hz, 2H), 2.28 (t, J = 6.2 Hz, 2H), 2.22 (t, J = 7.7 Hz, 2H), 1.99 (m, 2H), 1.47–1.66 (m, 4H), 1.39 (m, 2H), 0.82 (s, 9H), −0.07 (s, 3H), −0.23 (s, 3H). 13 C NMR (125 MHz, CDCl 3 ) δ 200.2, 166.7, 139.1, 130.1, 128.2, 126.3, 126.0, 75.1, 73.1, 71.4, 41.6, 38.3, 37.6, 29.9, 29.8, 27.1, 26.2, 26.1, 23.0, 18.4, −4.5, −5.0. FT-IR (neat) 3027, 2927, 2855, 1669, 1624, 1496, 1471, 1454, 1428, 1360, 1346, 1250, 1191, 1110, 1083, 1047, 992, 939, 887, 830, 809, 775, 749, 598 cm −1 . ESI MS ( m/z ) 431.3 [M+1] + .
3-{5-[2-(tert-Butyldimethylsilanyloxy)-3-isopropoxypropoxy]-pentyl}-cyclohex-2-enone (7bs, entry 9). 1 H NMR (500 MHz, CDCl 3 ) δ 5.78 (s, 1H), 3.73–3.85 (m, 1H), 3.41–3.53 (m, 1H), 3.32–3.36 (m, 4H), 3.20–3.30 (m, 2H), 2.28 (m, 2H), 2.19 (t, J = 5.6 Hz, 2H), 2.13 (t, J = 7.9 Hz, 2H), 1.90 (m, 2H), 1.36–1.50 (m, 4H), 1.20–1.35 (m, 2H), 1.05 (2d, 6H), 0.80 (s, 9H), −0.08 (s, 3H), 0.01 (s, 3H). 13 C NMR (125 MHz, CDCl 3 ) δ 204.8, 171.4, 130.4, 77.9, 76.6, 76.1, 75.9, 75.0, 428, 42.0, 34.4, 34.2, 31.5, 30.6, 30.5, 30.4, 27.4, 26.8, 22.9, 0.1, 0.0. FT-IR (neat) 2928, 2856, 1669, 1624, 1462, 1428, 1368, 1346, 1326, 1250, 1191, 1120, 1004, 938, 886, 833, 811, 776, 665, 572, 500 cm −1 . ESI MS ( m/z ) 413.3 [M+1] + .
3-{5-[2-(tert-Butyldimethylsilanyloxy)-3-phenylpropoxy]-pentyl}-6-benzylcyclohex-2-enone (7cq, entry 10). 1 H NMR (500 MHz, CDCl 3 ) δ 6.98–7.15 (m, 4H), 6.96 (m, 6H), 5.90 (s, 1H), 3.84 (m, 1H), 3.38 (td, J = 6.6, 3.0 Hz, 2H), 3.25–3.28 (m, 2H), 2.88 (dd, J = 13.4, 4.8 Hz, 1H), 2.62 (dd, J = 13.4, 7.5 Hz, 1H), 2.45 (m, 2H), 2.22 (m, 2H), 2.17 (m, 2H), 1.83 (m, 1H), 1.55–1.62 (m, 4H), 1.45–1.54 (m, 2H), 1.32–1.42 (m, 2H), 0.78 (s, 9H), −0.07 (s, 3H), −0.22 (s, 3H). 13 C NMR (125 MHz, CDCl 3 ) δ 201.0, 165.7, 140.4, 139.1, 130.1, 129.5, 128.6 (overlap), 128.3, 126.3, 125.6, 75.1, 73.1, 71.4, 47.9, 41.6, 38.0, 35.7, 29.7, 29.4, 27.3, 27.1, 26.2, 26.1, 18.4, −4.5, −5.0. FT-IR (neat) 3026, 2927, 2855, 1667, 1629, 1602, 1495, 1471, 1453, 1360, 1250, 1210, 1110, 1083, 1030, 992, 939, 887, 831, 809, 775, 740, 698, 665, 556, 510 cm −1 . ESI MS ( m/z ) 521.3 [M+1] + .
3-{5-[2-(tert-Butyldimethylsilanyloxy)-3-isopropoxypropoxy]-pentyl}-6-benzylcyclohex-2-enone (7cs, entry 11). 1 H NMR (500 MHz, CDCl 3 ) δ 7.22 (m, 2H), 7.13 (m, 3H), 5.84 (s, 1H), 3.83 (m, 1H), 3.58 (m, 2H), 3.30–3.36 (m, 4H), 3.30–3.40 (m, 3H), 2.43–2.53 (m, 2H), 2.23 (m, 2H), 2.20 (t, J = 5.2 Hz, 2H), 1.93 (m, 1H), 1.53–1.62 (m, 2H), 1.52 (m, 2H), 1.38 (m, 2H), 1.15–1.19 (2d, 6H), 0.89 (s 9H), 0.05 (s, 3H), −0.05 (s, 3H). 13 C NMR (125 MHz, CDCl 3 ) δ 201.0, 165.8, 140.4, 129.5, 128.5, 126.3, 125.5, 73.5, 72.2, 71.7, 71.3, 70.5, 47.9, 38.0, 35.7, 29.7, 29.3, 27.3, 27.1, 26.1, 26.1, 22.3, 22.3, 18.5, −4.4 (overlap). FT-IR (neat) 2927, 2856, 1668, 1453, 1367, 1250, 1211, 1121, 1004, 938, 886, 834, 811, 776, 739, 599, 665, 512 cm −1 . ESI MS ( m/z ) 503.4 [M+1] + .
Preparation of 3-(5-(2-Hydroxybutoxy)pentyl)cyclopent-2-enone (8ap, entry 1, General procedure). Similarly to the preparation of 3-{5-[2-( tert -butyldimethylsilanyloxy)-butoxy]-pentyl}-cyclopent-2-enone (7ap), except for the use of HF-pyridine in place of triethylamine in the desilylation step, 3-(5-(2-hydroxybutoxy)pentyl)cyclopent-2-enone 8ap was obtained (69 mg, 58%). 1 H NMR (500 MHz, CDCl 3 ) δ 5.99 (s, 1H), 3.73 (m, 1H), 3.40–3.60 (m, 3H), 3.30 (t, J = 8.9 Hz, 1H), 2.59 (m, 2H), 2.51–2.40 (m, 4H), 2.27 (br, 1H), 1.56–1.72 (m, 4H), 1.39–1.56 (m, 4H), 0.98 (t, J = 7.4 Hz, 3H). 13 C NMR (125 MHz, CDCl 3 ) δ 210.4, 183.1, 129.8, 75.0, 71.9, 71.3, 35.6, 33.7, 31.8, 29.6, 27.2, 26.4, 26.2, 10.1. FT-IR (neat) 3379, 2928, 2858, 1702, 1673, 1612, 1461, 1436, 1235, 1181, 1117, 1028, 996, 919, 841, 748, 720, 694, 537, 504 cm −1 . ESI MS ( m/z ) 241.2 [M+1] + .
3-(5-(2-Hydroxy-3-phenylpropoxy)pentyl)cyclopent-2-enone (8aq, entry 2). 1 H NMR (500 MHz, CDCl 3 ) δ 7.34–7.28 (m, 2H), 7.23 (m, 3H), 5.95 (s, 1H), 4.02 (m, 1H), 3.42–3.50 (m, 3H), 3.31 (m, 1H), 2.80 (m, 2H), 2.58 (m, 2H), 2.42–2.46 (m, 4H), 2.32–2.25 (br, 1H), 1.70–1.59 (m, 4H), 1.42 (m, 2H). 13 C NMR (125 MHz, CDCl 3 ) δ 210.4, 183.1, 138.2, 129.8, 129.6, 128.7, 126.7, 74.3, 71.6, 71.4, 40.2, 35.6, 33.7, 31.8, 29.6, 27.1, 26.2. FT-IR (neat) 3422, 3026, 2929, 2859, 1702, 1672, 1611, 1495, 1453, 1435, 1407, 1337, 1283, 1236, 1183, 1117, 1080, 1030, 989, 842, 744, 699, 604, 541, 503 cm −1 . ESI MS ( m/z ) 303.2 [M+1] + .
3-(5-(2-Hydroxy-3-isopropoxypropoxy)pentyl)cyclopent-2-enone (8as, entry 4). 1 H NMR (500 MHz, CDCl 3 ) δ 5.95 (s, J = 2.4 Hz, 1H), 3.93 (m, 1H), 3.60 (m, 1H), 3.57–3.54 (m, 6H), 2.59 (m, 2H), 2.40–2.44 (m, 4H), 1.51–1.70 (m, 6H), 1.40 (m, 2H), 1.03–1.13 (2d, 6H). 13 C NMR (125 MHz, CDCl 3 ) δ 210.5, 183.3, 132.4, 72.4, 71.7, 71.0, 69.9, 69.5, 35.5, 33.7, 31.8, 29.7, 27.1, 26.1, 23.0, 22.2. FT-IR (neat) 2930, 2860, 1705, 1674, 1613, 1437, 1367, 1334, 1179, 1117, 1081, 997, 748, 720, 694, 539 cm −1 . ESI MS ( m/z ) 285.2 [M+1] + .
3-(5-(2-Hydroxybutoxy)pentyl)cyclohex-2-enone (8bp, entry 7). 1 H NMR (500 MHz, CDCl 3 ) δ 5.85 (s, 1H), 3.72 (m, 1H), 3.40–3.57 (m, 3H), 3.23 (m, 1H), 2.38 (t, 2H), 2.29 (t, 2H), 2.22 (m, 2H), 2.00 (m, 2H), 1.62 (m, 2H), 1.57 (m, 2H), 1.50 (m, 2H), 1.40 (m, 2H), 0.98 (t, J = 7.5, 3H). 13 C NMR (125 MHz, CDCl 3 ) δ 200.2, 166.6, 125.9, 75.0, 71.9, 71.3, 38.2, 37.6, 29.9, 29.6, 26.9, 26.4, 26.0, 22.9, 10.1. FTIR (neat) 3412, 2928, 2859, 1703, 1673, 1612, 1460, 1437, 1407, 1236, 1182, 1116, 1029.66, 978, 919, 842, 748, 721, 595, 540 cm −1 . ESI MS (m/z) 255.2 [M+1] + .
3-(5-(2-Hydroxy-3-phenylpropoxy)pentyl)cyclohex-2-enone (8bq, entry 8). 1 H NMR (500 MHz, CDCl 3 ) δ 7.31 (m, 2H), 7.25–7.19 (m, 3H), 5.88 (s, 1H), 4.02 (m, 1H), 3.36–3.54 (m, 3H), 3.31 (dd, J = 9.6, 7.2 Hz, 1H), 2.79 (m, 3H), 2.38 (m, 2H), 2.35 (m, 2H), 2.22 (t, J = 7.7 Hz, 2H), 1.98 (quintet, J = 6.3 Hz, 2H), 1.60 (m, 2H), 1.57 (m, 2H), 1.40 (m, 2H). 13 C NMR (125 MHz, CDCl 3 ) δ 200.2, 166.6, 138.2, 129.6, 128.7, 126.7, 126.0, 74.3, 71.2, 71.4, 40.2, 38.2, 37.6, 29.9, 29.7, 26.95, 26.1, 23.0. FT-IR (neat) 3434, 3026, 2932, 2860, 1662, 1622, 1495, 1453, 1427, 1371, 1347, 1325, 1253, 1191, 1117, 1081, 1030, 965, 886, 744, 699, 604, 501 cm −1 . ESI MS ( m/z ) 317.2 [M+1] + .
3-(5-(2-Hydroxy-3-isopropoxypropoxy)pentyl)cyclohex- 2-enone (8bs, entry 9). 1 H NMR (500 MHz, CDCl 3 ) δ 5.87 (s, 1H), 3.92 (m, 1H), 3.60 (m, 1H), 3.40–3.57 (m, 6H), 2.49 (d, J = 4.0 Hz, 1H), 2.38 (t, 2H), 2.28 (t, J = 6.1 Hz, 2H), 2.22 (t, J = 7.6 Hz, 2H), 1.99 (quintet, J = 6.3 Hz, 2H), 1.60 (m, 2H), 1.57 (m, 2H), 1.38 (m 2H), 1.15–1.21 (2d, 6H). 13 C NMR (125 MHz, CDCl 3 ) δ 200.3, 166.9, 125.9, 72.4, 72.2, 71.5, 70.0, 69.5, 38.2, 37.6, 29.9, 29.6, 27.0, 26.0, 23.0, 22.3. FT-IR: 3440, 2931, 2862, 1665, 1623, 1455, 1428, 1368, 1346, 1324, 1253, 1191, 1175, 1118, 1080, 965, 886, 823, 722, 542, 500 cm −1. ESI MS ( m/z) 299.2 [M+1] + .
Supporting Information. 1 H and 13 C NMR spectra of selected compounds are provided.
Acknowledgements
This work was supported by the grant from Sungshin Women’s University in 2012.
References
Jung S. H. , Jang S. Y. 2010 Bull. Korean Chem. Soc. 31 3431 -    DOI : 10.5012/bkcs.2010.31.11.3431
Kozikowski A. P. , Jung S. H. 1986 J. Org. Chem. 51 3400 -    DOI : 10.1021/jo00367a040
Tetrahyropyran was purchased from Sigma-Aldrich and distilled over sodium benzophenone ketyl prior to use